Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.
View Top Employees from Syndesi Therapeutics| Website | http://www.syndesitherapeutics.com |
| Revenue | $5 million |
| Employees | 10 (1 on RocketReach) |
| Founded | 2018 |
| Phone | (321) 028-0238 |
| Technologies |
JavaScript,
HTML,
Twitter
+8 more
(view full list)
|
| Industry | Biotechnology, Drug Development, Pharmaceuticals, Science and Engineering, CNS, Healthcare, Health Care |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies |
Looking for a particular Syndesi Therapeutics employee's phone or email?
Syndesi Therapeutics Questions
The Syndesi Therapeutics annual revenue was $5 million in 2023.
Jonathan Savidge is the CEO of Syndesi Therapeutics.
1 people are employed at Syndesi Therapeutics.
The NAICS codes for Syndesi Therapeutics are [32, 325, 3254, 32541].
The SIC codes for Syndesi Therapeutics are [283, 28].
Top Syndesi Therapeutics Employees
-
ViewJonathan Savidge
Chief Executive Officer at Syndesi Therapeutics
Oxford, Oxfordshire, United Kingdom2
Related Companies
